Is Astellas Pharma (4503) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 19.3% / 30% | 5.1% / 30% | 14.7% / 30% | 0.41% / 5% | ✓ HALAL |
| DJIM | 19.3% / 33% | 5.1% / 33% | 14.7% / 33% | 0.41% / 5% | ✓ HALAL |
| MSCI | 24.9% / 33% | 6.5% / 33% | 18.9% / 33% | 0.41% / 5% | ✓ HALAL |
| S&P | 19.3% / 33% | 5.1% / 33% | 14.7% / 33% | 0.41% / 5% | ✓ HALAL |
| FTSE | 24.9% / 33% | 6.5% / 33% | 18.9% / 50% | 0.41% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 81.0% | |
| Operating Margin | 23.6% | |
| Net Margin | 15.7% | |
| Return on Equity (ROE) | 19.8% | |
| Return on Assets (ROA) | 7.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $194.5B |
| Free Cash Flow | $137.2B |
| Total Debt | $831.4B |
| Debt-to-Equity | 41.1 |
| Current Ratio | 1.1 |
| Total Assets | $3.3T |
Price & Trading
| Last Close | JPY 2,535.00 |
| 50-Day MA | JPY 2,380.39 |
| 200-Day MA | JPY 1,872.49 |
| Avg Volume | 7.2M |
| Beta | 0.1 |
|
52-Week Range
JPY 1,243.50
| |
About Astellas Pharma (4503)
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Purification Calculator
As a halal stock with 0.41% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Astellas Pharma (4503) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Astellas Pharma is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Astellas Pharma's debt ratio?
Astellas Pharma's debt ratio is 19.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.9%.
Does Astellas Pharma require dividend purification?
Yes, Astellas Pharma has an impermissible income ratio of 0.41%, which means 0.41% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Astellas Pharma's key financial metrics?
Astellas Pharma has a market capitalization of $4.7T, trailing P/E ratio of 37.6, and revenue of $1.9T. The company maintains a gross margin of 81.0% and a net margin of 15.7%. Return on equity stands at 19.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.